Iovance Biotherapeutics Statistics

Total Valuation

Iovance Biotherapeutics has a market cap or net worth of GBP 1.48 billion. The enterprise value is 1.22 billion.

Market Cap	1.48B
Enterprise Value	1.22B

Important Dates

The next estimated earnings date is Monday, February 24, 2025.

Earnings Date	Feb 24, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+30.80%
Shares Change (QoQ)	+6.48%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	224.94M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
PB Ratio	n/a
P/TBV Ratio	4.26
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-4.00
EV / Sales	16.59
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-4.38

Financial Position

The company has a current ratio of 4.22, with a Debt / Equity ratio of 0.10.

Current Ratio	4.22
Quick Ratio	3.84
Debt / Equity	0.10
Debt / EBITDA	n/a
Debt / FCF	-0.21
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -56.65% and return on invested capital (ROIC) is -33.47%.

Return on Equity (ROE)	-56.65%
Return on Assets (ROA)	-29.15%
Return on Capital (ROIC)	-33.47%
Revenue Per Employee	121,704
Profits Per Employee	-549,190
Employee Count	557
Asset Turnover	0.10
Inventory Turnover	3.47

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -23.80% in the last 52 weeks. The beta is 0.59, so Iovance Biotherapeutics's price volatility has been lower than the market average.

Beta (5Y)	0.59
52-Week Price Change	-23.80%
50-Day Moving Average	8.03
200-Day Moving Average	9.51
Relative Strength Index (RSI)	29.38
Average Volume (20 Days)	35,386

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	7.87

Income Statement

In the last 12 months, Iovance Biotherapeutics had revenue of GBP 67.79 million and -305.90 million in losses. Loss per share was -1.10.

Revenue	67.79M
Gross Profit	6.00M
Operating Income	-320.79M
Pretax Income	-310.48M
Net Income	-305.90M
EBITDA	-304.65M
EBIT	-320.79M
Loss Per Share	-1.10

Full Income Statement

Balance Sheet

The company has 296.57 million in cash and 58.90 million in debt, giving a net cash position of 237.67 million.

Cash & Cash Equivalents	296.57M
Total Debt	58.90M
Net Cash	237.67M
Net Cash Per Share	n/a
Equity (Book Value)	577.07M
Book Value Per Share	1.89
Working Capital	283.91M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -271.32 million and capital expenditures -7.78 million, giving a free cash flow of -279.10 million.

Operating Cash Flow	-271.32M
Capital Expenditures	-7.78M
Free Cash Flow	-279.10M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross Margin	8.85%
Operating Margin	-473.22%
Pretax Margin	-458.01%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Iovance Biotherapeutics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-30.80%
Shareholder Yield	-30.80%
Earnings Yield	-20.64%
FCF Yield	-18.83%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Iovance Biotherapeutics has an Altman Z-Score of 2.92. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.92
Piotroski F-Score	n/a